Last updated on December 2017

Combined Phase 2B / 3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis

Brief description of study

This study is designed to evaluate the effect of treatment with filgotinib on the induction and maintenance of remission in subjects with moderately to severely active Ulcerative Colitis (UC).

For those patients who complete the trial, they will be eligible for the long-term extension study, for up to 144 additional weeks. 

Clinical Study Identifier: TX155016

Contact Investigators or Research Sites near you

Start Over

Jo-Anne E. Tiamzon, BS, CCRC

Gastroenterology Associates of Tidewater
Chesapeake, VA USA
  Connect »